Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...

As well as the economic and employment benefits, BioNTech’s UK investment is expected to deliver tangible improvements in healthcare. The company’s work in personalised cancer immunotherapies, already ...